Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled time : 12:30 save search
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting
Published: 2022-03-24 (Crawled : 12:30) - biospace.com/
AMRX | $5.36 -1.83% -1.87% 840K
|
Health Technology
|
| O: 0.5%
H: 0.25%
C: 0.25%
ipx-203 trial results phase 3
Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
Published: 2022-03-21 (Crawled : 12:30) - globenewswire.com
AEZS | $1.97 0.73% 6K
|
Health Technology
|
| O: 0.93%
H: 3.04%
C: -1.39%
ongoing trial one growth hormone growth phase 3 set hormone diagnostic
BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A
Published: 2022-03-17 (Crawled : 12:30) - investors.biomarin.com
BMRN S | $90.08 -0.43% -0.43% 940K
|
Health Technology
|
| O: 1.26%
H: 1.69%
C: -0.02%
gene therapy trial one therapy results phase 3
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial
Published: 2022-03-14 (Crawled : 12:30) - biospace.com/
NKTR | $1.3 -3.7% -3.85% 3.6M
|
Health Technology
|
| O: -54.79%
H: 0.0%
C: 0.0%
io-001 announcement trial conference therapeutics phase 3
Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEBTopline data from VIITAL™ expected in the third quarter of 2022
Published: 2022-03-14 (Crawled : 12:30) - biospace.com/
ABEO | $7.55 -4.79% -5.03% 250K
|
Health Technology
|
| O: -6.93%
H: 0.0%
C: 0.0%
eb-101 therapeutics topline phase 3 enroll
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
Published: 2022-03-14 (Crawled : 12:30) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
NKTR | $1.3 -3.7% -3.85% 3.6M
|
Health Technology
|
| O: -54.79%
H: 0.0%
C: 0.0%
io-001 opdivo trial phase 3 nivolumab
Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress
Published: 2022-03-07 (Crawled : 12:30) - biospace.com/
RPTX 4 | $3.025 -5.76% -6.12% 140K
|
Health Technology
|
| O: -5.48%
H: 5.02%
C: 1.56%
rp-3500 500 trial therapeutics phase 1 therapy cancer phase 2 phase 3
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial
Published: 2022-03-07 (Crawled : 12:30) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.5%
H: 1.66%
C: 0.93%
ynote-716 keytruda trial therapy phase 3
RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial
Published: 2022-02-22 (Crawled : 12:30) - renovorx.com
RNXT | $1.19 5.07% 5.3K
|
|
| O: 1.95%
H: 3.26%
C: -3.28%
ongoing trial cancer phase 3 pancreatic enroll
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy
Published: 2022-02-16 (Crawled : 12:30) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.0%
H: 0.91%
C: -0.25%
cardio trial mavacamten topline results positive topline phase 3
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
Published: 2022-01-19 (Crawled : 12:30) - globenewswire.com
AGNPF | $0.0672 178.69% 100
|
Health Technology
|
| O: 1.33%
H: 1.73%
C: -14.06%
als trial approval stroke phase 1 phase 2 phase 3
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
Published: 2022-01-14 (Crawled : 12:30) - biospace.com/
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: 0.0%
results phase 3
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
Published: 2022-01-12 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: 0.0%
H: 0.0%
C: 0.0%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.77%
H: 1.46%
C: 0.55%
phase 3 topline order
Red Pine Updates on its 2022 Phase 1 Drill Program
Published: 2022-01-05 (Crawled : 12:30) - globenewswire.com
PZG | $0.441 -0.9% 0.0% 54K
|
Non-Energy Minerals
|
| O: 1.45%
H: 8.26%
C: -1.75%
phase 1 phase 2 phase 3 program
Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January
Published: 2022-01-05 (Crawled : 12:30) - globenewswire.com
OCUP | $1.675 -3.74% -3.88% 240K
|
Health Technology
|
| O: -0.26%
H: 2.49%
C: -3.93%
nyxol trial phase 3 enroll
The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
Published: 2022-01-04 (Crawled : 12:30) - globenewswire.com
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
mycapssa trial diabetes positive results positive results phase 3 lancet
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
Published: 2021-12-30 (Crawled : 12:30) - globenewswire.com
IMVT 4 | $28.34 -0.32% -0.32% 1.2M
|
Health Technology
|
| O: -0.51%
H: 7.98%
C: 7.59%
trial phase 3
BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study
Published: 2021-12-27 (Crawled : 12:30) - biospace.com/
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: -68.88%
H: 4.03%
C: -9.97%
topline results results topline phase 3 pharma
BioXcel Therapeutics Initiates Pivotal Phase 3 Program of BXCL501 for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Published: 2021-12-15 (Crawled : 12:30) - globenewswire.com
BTAI | $2.56 -1.16% -1.17% 240K
|
Health Technology
|
| O: -3.82%
H: 8.09%
C: 7.79%
bxcl501 alzheimer treatment therapeutics disease cel phase 3 alzheimer’s alzheimer's disease alzheimer's
TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
TGTX | News | $14.0 1.3% 1.29% 3.5M
|
Health Technology
|
| O: -5.49%
H: 2.43%
C: -2.68%
ema trial therapeutics phase 3
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.